The PRAME-AS knockout cells showed a decrease in migration, proliferation, stemness, and viability. by Zahra Hosseininia (22265113)

NSC population and proliferation decrease drastically during the second postnatal week of DG development. by Cristina Medina-Menéndez (21800157)

Expression of lipid biosynthetic genes is decreased with polyamine depletion. by Yazmin E. Cruz-Pulido (20285238)

Subjects:

Long-term anti-nucleocapsid response by baseline patient characteristics. by Elizabeth S. Munroe (21568166)

Subjects:

Analysis of immune cells in brown trout kidney from the three fish rearing backgrounds (W, W:F, F) with flow cytometry. by Helena Saura Martinez (22305113)

Subjects:

The capture efficiency of BioMagnetic solutions FerroSelect in PBS/1% BSA and whole blood showed a decrease in capture efficiency when moving to whole blood. by Peng Liu (120506)

Plots of FEV₁ (upper left), FVC (upper right), TLC (lower left) and TLCO (lower right) values expressed in % pred. (<i>y</i>-axis) against <i>z</i>-scores (<i>x</i>-axis... by Piotr W. Boros (21446186)

Subjects:

Antibody and antigen responses to Ensovibep vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to Lufotrelvir vs placebo day 1–90. by Elizabeth S. Munroe (21568166)

Subjects:

Pan-neuronal <i>dMaf1</i> knockdown decreases <i>dMaf1</i> mRNA level in brains and consistently extends lifespan. by Bowen Xu (5903801)

The G215S mutation decreases packaging of N and growth in primary differentiated human bronchial cells. by Hannah C. Kubinski (21213168)

Data Sheet 1_Decreased cigarette smoking may partially explain the increased prevalence of antinuclear antibodies in the United States.pdf by Gregg E. Dinse (4500940)

“…</p>Discussion<p>Although smoking causes harmful health effects, ANA data are consistent with smoking playing a role in decreasing autoimmunity. Recent vaping among adolescents may partially explain their large increase in ANA prevalence. …”

Antibody and antigen responses to nMAb vs placebo day 1–90 for Bamlanivimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Sotrovimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Amubarvimab/ Romlusevimab. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses to nMAb vs placebo day 1–90 for Tixagevimab/ Cilgavimab. by Elizabeth S. Munroe (21568166)

Subjects:

Quantitative antibody and antigen responses to nMAb vs placebo day 1-90: Pooled analysis of neutralizing monoclonal antibodies. by Elizabeth S. Munroe (21568166)

Subjects:

Antibody and antigen responses after treatment with nMAb vs placebo, day 1-90 (pooled nMAb treatments). by Elizabeth S. Munroe (21568166)

Subjects:

Hazard ratios (HR) for all-cause mortality with 95% confidence intervals from Cox regression models using the 2005 vs. the 2022 guidelines for grading severity, normal FVC (<i>n</i... by Piotr W. Boros (21446186)

Subjects:

Decreased virulence observed during <i>in planta</i> infection with <i>ΔFgknr4</i>. by Erika Kroll (20537020)